Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.33 |
| ▸ | HPGD | P15428 | 4/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.31 |
| ▸ | MAPT | P10636 | 4/20 | 0.31 |
| ▸ | MEN1 | O00255 | 3/20 | 0.31 |
| ▸ | RAB9A | P51151 | 3/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.31 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.31 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1137466 | 0.82 | PKM (0.35) | SMN1; SMN2HPGDALDH1A1KMT2AMAPT | |
| SCHEMBL29398201 | 0.76 | LMNA (0.37) | LMNASMN1; SMN2HPGDHSD17B10ALDH1A1 | |
| SCHEMBL109627 | 0.76 | LMNA (0.37) | LMNASMN1; SMN2HPGDHSD17B10ALDH1A1 | |
| SCHEMBL20384698 | 0.76 | LMNA (0.37) | LMNASMN1; SMN2HPGDHSD17B10ALDH1A1 | |
| Hydrochloric Acid SCHEMBL30767122 | 0.76 | LMNA (0.36) | LMNASMN1; SMN2HPGDHSD17B10ALDH1A1 | |
| SCHEMBL18958956 | 0.74 | LMNA (0.40) | LMNASMN1; SMN2HPGDHSD17B10ALDH1A1 | |
| SCHEMBL1395632 | 0.73 | ALDH1A1 (0.54) | LMNASMN1; SMN2HPGDHSD17B10ALDH1A1 | |
| SCHEMBL16132816 | 0.73 | ALDH1A1 (0.54) | LMNASMN1; SMN2HPGDHSD17B10ALDH1A1 | |
| SCHEMBL25854290 | 0.73 | EHMT2 (0.44) | LMNASMN1; SMN2HPGDHSD17B10ALDH1A1 | |
| SCHEMBL2208529 | 0.73 | LMNA (0.34) | LMNASMN1; SMN2HPGDHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390370-B1 | METHODS FOR PREPARATION OF CYTOTOXIC CONJUGATES OF MAYTANSINOIDS AND CELL BINDING AGENTS | IMMUNOGEN INC (US) | 2016-04-13 | — | — | EP | disclosed |
| EP-2348024-B1 | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents | IMMUNOGEN INC (US) | 2015-07-29 | — | — | EP | disclosed |
| EP-2348024-A2 | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents | ImmunoGen, Inc. (US) | 2011-07-27 | — | — | EP | disclosed |
| US-7368565-B2 | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents | IMMUNOGEN INC. (US) | 2008-05-06 | — | — | US | disclosed |
| EP-1390370-A4 | METHODS FOR PREPARATION OF CYTOTOXIC CONJUGATES OF MAYTANSINOIDS AND CELL BINDING AGENTS | IMMUNOGEN INC (US) | 2005-07-06 | — | — | EP | disclosed |
| EP-1390370-A1 | METHODS FOR PREPARATION OF CYTOTOXIC CONJUGATES OF MAYTANSINOIDS AND CELL BINDING AGENTS | Immunogen, Inc. (US) | 2004-02-25 | — | — | EP | disclosed |
| US-20030055226-A1 | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents | IMMUNOGEN, INC. | 2003-03-20 | — | — | US | disclosed |
| WO-2002098883-A1 | METHODS FOR PREPARATION OF CYTOTOXIC CONJUGATES OF MAYTANSINOIDS AND CELL BINDING AGENTS | IMMUNOGEN, INC. (US) | 2002-12-12 | — | — | WO | disclosed |
| US-6441163-B1 | COUPLING MAYTANSINOIDS HAVING DISULFIDE LINKER BEARING REACTIVE MOIETY TO SUCH AS ANTIBODIES WITHOUT PRIOR MODIFICATION OF SAID ANTIBODY; ONE-STEP, HIGH YIELD, LOWER COST | IMMUNOGEN, INC. | 2002-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055226-A1 | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents | SPR, SELPLG, CD2BP2 | LMNA 2357/4885SMN1; SMN2 1810/4885HPGD 1406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.